Loading...
Loading...
PHAR| Name | Value |
|---|---|
| Revenues | 81.9M |
| Cost of Revenue | 14.8M |
| Gross Profit | 67.1M |
| Operating Expense | 66.5M |
| Operating I/L | 0.6M |
| Other Income/Expense | -3.1M |
| Interest Income | 1.6M |
| Pretax | -2.7M |
| Income Tax Expense | 0.7M |
| Net Income/Loss | -2.7M |
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases and unmet medical needs. Its lead product, Ruconest, is a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema. The company also develops rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19, leniolisib for activated PI3K delta syndrome, and alpha-glucosidase therapy for pompe and fabry diseases. Pharming Group N.V. has a development collaboration and license agreement with Novartis and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for hereditary angioedema.
